

## Cover for Oncology Innovation Benefit 2023

### Who we are

LA Health Medical Scheme (referred to as 'the Scheme'), registration number 1145, is a non-profit organisation, registered with the Council for Medical Schemes. Discovery Health (Pty) Ltd (referred to as 'the administrator'), is a separate company who is registered as an authorised financial services provider (registration number 1997/013480/07). We take care of the administration of your membership for the Scheme.

### Contact us

You can call us on **0860 103 933** or visit [www.lahealth.co.za](http://www.lahealth.co.za) for more information.

### Overview

The Oncology Innovation Benefit gives members on the LA Comprehensive and LA Core options access to a defined list of high-cost medicines and new technologies.

Approval is subject to meeting clinical entry criteria and requests may be reviewed by an external panel for consideration for funding from this benefit. We will pay up to 75% of the LAHealth Rate. If your healthcare provider charges more than what we pay, you will need to pay the difference. This amount could be more than 25% if your treatment cost is above the LA Health Rate. These claims will accumulate to your R400 000 cover amount at 75% of the LA Health Rate.

Once your treatment costs exceed your R400 000 cover amount, we will continue to pay 75% of the LA Health Rate for approved medicine

### Defined medicines are covered from the Oncology Innovation Benefit

Members who meet the requirements have cover for the following oncology medicines:

Indication	Product name	Clinical Criteria
Locally Advanced or Metastatic non small cell lung cancer	Tagrisso	Locally advanced or metastatic non-small cell lung cancer (NSCLC) and as first line therapy and (EGFR) exon 19 deletions or exon 21 (L858R) positive
	Tagrisso	
Hodgkin's Lymphoma	Keytruda solution for infusion vial 4ml	Classical Hodgkin lymphoma, and following at least two prior therapies when ASCT is not a treatment option
T-cell Lymphoma	Adcetris powder for reconstitution vial	Systemic anaplastic large cell lymphoma (sALCL)
Advanced Renal Cell Carcinoma	Keytruda solution for infusion vial 4ml	Advanced renal cell carcinoma (RCC)
		as first line treatment, and in combination with axitinib
Metastatic Head and Neck Squamous Cell Carcinoma	Keytruda solution for infusion vial 4ml	Head and neck squamous cell carcinoma (HNSCC), as first line treatment, and monotherapy, or in combination with platinum and 5-fluorouracil (5-FU) CPS < 20
	Keytruda solution for infusion vial 4ml	HNSCC with disease progression on or after platinum containing chemotherapy, as monotherapy in adults whose tumours express PD-L1 with a ≥50% TPS
Metastatic Colorectal Cancer	Keytruda solution for infusion vial 4ml	Unresectable or metastatic colorectal cancer, with
		microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), and as first line treatment

Indication	Product name	Clinical Criteria
<b>Metastatic Ovarian Cancer</b>	Lynparza	Epithelial ovarian, fallopian tube or primary peritoneal cancer, with a mutation in BRCA1, BRCA2, or both complete response or partial response, to first line platinum-based chemotherapy as monotherapy
	Lynparza	Epithelial ovarian, fallopian tube or primary peritoneal cancer, platinum sensitive relapsed, with a mutation in BRCA1, BRCA2, or both complete response or partial response, to first line platinum-based chemotherapy as monotherapy
<b>Acute Myeloid Leukemia</b>	Venclexta 4x7 day wallet Venclexta	Acute Myeloid Leukemia $\geq 75$ or not eligible for intensive chemotherapy in combination with LDAC
	Venclexta 4x7 day wallet Venclexta	Acute Myeloid Leukemia $\geq 18$ previously untreated patients, and ineligible for intensive chemotherapy in combination with Azacitidine
<b>Metastatic triple-negative breast cancer</b>	Keytruda solution for infusion vial 4ml	Locally recurrent unresectable or metastatic triple-negative breast cancer, in adults whose tumours express PD-L1 with a CPS $\geq 10$ .
<b>Sickle cell disease</b>	Ryverna	Sickle cell disease, in Patients aged 16 years and over
<b>Oesophageal and gastro-oesophageal junction cancer</b>	Keytruda solution for infusion vial 4ml	Locally advanced unresectable or metastatic carcinoma of the oesophagus, or HER2-negative gastro-oesophageal junction adenocarcinoma, previously untreated patients, and in combination with platinum and 5-fluorouracil (5-FU) in adults whose tumours express PD-L1 with a CPS $\geq 10$ .

## **Tell us about your cancer treatment and we'll tell you how we will cover it**

If you need cancer treatment, your cancer specialist must send us your treatment plan for approval before starting with the treatment. We will only fund your cancer treatment from the Oncology Benefit if your treatment plan has been approved and meets the terms and conditions of the Scheme.

All costs related to your approved cancer treatment including Prescribed Minimum Benefit treatment during the 12-month period, will add up to the 12-month cycle cover amount.

We cover all cancer-related healthcare services up to 100% of the LA Health Rate. You might have a co-payment if your healthcare professional charges more than this rate.

## **Complaints process**

You may lodge a complaint or query with LA Health Medical Scheme directly on 0860 103 933 address a complaint in writing to the Principal Officer at the Scheme's registered address. Should your complaint remain unresolved, you may lodge a formal dispute by following the LA Health Medical Scheme internal disputes process.

You may, as a last resort, approach the Council for Medical Schemes for assistance.  
Council for Medical Schemes Complaints Unit, Block A, Eco Glades 2 Office Park, 420 Witch-Hazel Avenue, Eco Park, Centurion, 0157 / 0861 123 267 / [complaints@medicalschemes.co.za](mailto:complaints@medicalschemes.co.za) / [www.medicalschemes.co.za](http://www.medicalschemes.co.za)